Scholarlink

<p>Atopic dermatitis (AD), a chronic, relapsing, inflammatory skin disease, occurs in up to 20% of children. 2% crisaborole ointment, a novel phosphodiesterase-4 inhibitor, has shown therapeutic benefits in managing AD; however, there are limited data on its sustained use and its impact on relapse prevention following AD resolution. This Adis Summary of Research summarizes the findings of a randomized, open-label, multicentre study conducted in China that investigated the efficacy and tolerability of a proactive treatment strategy with 2% crisaborole ointment in children aged 2–17&#xa0;years with mild-to-moderate AD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adis Summary of Research: Efficacy and safety of proactive therapy with 2% crisaborole ointment in children with mild-to-moderate atopic dermatitis: a randomized controlled study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月18日

查看全文
  • Sheridan M. Hoy

摘要

Atopic dermatitis (AD), a chronic, relapsing, inflammatory skin disease, occurs in up to 20% of children. 2% crisaborole ointment, a novel phosphodiesterase-4 inhibitor, has shown therapeutic benefits in managing AD; however, there are limited data on its sustained use and its impact on relapse prevention following AD resolution. This Adis Summary of Research summarizes the findings of a randomized, open-label, multicentre study conducted in China that investigated the efficacy and tolerability of a proactive treatment strategy with 2% crisaborole ointment in children aged 2–17 years with mild-to-moderate AD.